Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 4, 2009, Pages 335-350

  Cheng, Jin Wei ^a   Xi, Gui Lin ^b   Wei, Rui Li ^a   Cai, Ji Ping ^a   Li, You ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

intraocular pressure; latanoprost; meta analysis; travoprost

Indexed keywords

LATANOPROST; TRAVOPROST;

BLEPHARITIS; BLURRED VISION; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; EYE COLOR; EYE IRRITATION; EYE PAIN; EYELASH; HAIR GROWTH; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; META ANALYSIS; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 70249136836     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.08.006     Document Type: Review

References (35)

1. The AGIS Investigators, and The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
2. Wax M.B., Camras C.B., Fiscella R.G., et al. Emerging perspectives in glaucoma: Optimizing 24-hour control of intraocular pressure. Am J Ophthalmol 133 Suppl (2002) S1-S10
3. Maier P.C., Funk J., Schwarzer G., et al. Treatment of ocular hypertension and open angle glaucoma: Meta-analysis of randomised controlled trials. BMJ 331 (2005) 134
4. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res. 17 (1998) 291-312
5. Zhang W.Y., Po A.L., Dua H.S., and Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85 (2001) 983-990
6. Davis T.L., and Sharif N.A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther. 15 (1999) 323-336
7. Holmstrom S., Buchholz P., Walt J., et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 21 (2005) 1875-1883
8. Li N., Chen X.M., Zhou Y., et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: Meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 34 (2006) 755-764
9. Denis P., Lafuma A., Khoshnood B., et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 23 (2007) 601-608
10. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated (September 2006). http://www.cochrane.org/resources/handbook/Handbook4.2.6Sep2006.pdf Accessed December 2, 2006
11. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 17 (1996) 1-12
12. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials. 7 (1986) 177-188
13. Netland P.A., Landry T., Sullivan E.K., et al., the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132 (2001) 472-484
14. Cardascia N., Vetrugno M., Trabucco T., et al. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: A 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Curr Ther Res Clin Exp. 64 (2003) 389-400
15. Parrish R.K., Palmberg P., Sheu W.P., and the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
16. Cellini M., Caramazza R., Bonsanto D., et al. Prostaglandin analogs and blood-aqueous barrier integrity: A flare cell meter study. Ophthalmologica 218 (2004) 312-317
17. Dubiner H.B., Sircy M.D., Landry T., et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 26 (2004) 84-91
18. Kong X., Sun X., and Meng F. A clinical study of travoprost (Travatan) in treating patients with primary open angle glaucoma or ocular hypertension. Zhongguo Shiyong Yan Ke Za Zhi. 22 (2004) 877-880
19. Arcieri E.S., Santana A., Rocha F.N., et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial. Arch Ophthalmol 123 (2005) 186-192
20. Chiselitá D., Antohi I., Medvichi R., and Danielescu C. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide: A prospective, randomized, masked, cross-over design study. Oftalmologia 49 (2005) 39-45
21. Garcfa-Feijoo J., Martínez-de-la-Casa J.M., Castillo A., et al. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin. 22 (2006) 1689-1697
22. Orzalesi N., Rossetti L., Bottoli A., and Fogagnolo P. Comparison of the effects of latanoprost, travo-prost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
23. Parmaksiz S., Yüksel N., Karabas V.L., et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 16 (2006) 73-80
24. Hepsen I.F., and Ozkaya E. 24-H IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye. 21 (2007) 453-458
25. Konstas A.G., Kozobolis V.P., Katsimpris I.E., et al. Efficacy and safety of latanoprost versus travo-prost in exfoliative glaucoma patients. Ophthalmology 114 (2007) 653-657
26. Koz O.G., Ozsey A., Yarangumeli A., et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: A 6-month clinical trial. Acta Ophthalmol Scand 85 (2007) 838-843
27. Maul E., Carrasco F.G., Costa V.P., et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther. 29 (2007) 1915-1923
28. Arcieri E.S., Pierre Filho P.T., Wakamatsu T.H., and Costa V.P. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye. 22 (2008) 179-183
29. Yildirim N., Sahin A., and Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma. 17 (2008) 36-39
30. Maier P.C., Funk J., Schwarzer G., et al. Treatment of ocular hypertension and open angle glaucoma: Meta-analysis of randomised controlled trials. BMJ 331 (2005) 134-139
31. Palmberg P. Evidence-based target pressures: How to choose and achieve them. Int Ophthalmol Clin. 44 (2004) 1-14
32. Cantor L. Achieving low target pressures with today's glaucoma medications. Surv Ophthalmol 48 Suppl 1 (2003) S8-S16
33. Waugh J., and Jarvis B. Travoprost. Drugs Aging 19 (2002) 465-471
34. discussion. Waugh J., and Jarvis B. Travoprost. Drugs Aging 19 (2002) 247-273
35. Whitson J.T. Travoprost-a new prostaglandin analogue for the treatment of glaucoma. Expert Opin Pharmacother 3 (2002) 965-977